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A number of  publications show that mice bearing progressive syngeneic tumors 
can acquire suppressor T  cells,  as measured by a  variety of assays (reviewed in 
1).  In support of this evidence, a  series of studies in this laboratory (2,  3) has 
shown  that  the  acquisition  of suppressor  T  cells  by a  tumor-bearing host  is 
responsible for the failure of passively transferred, tumor-sensitized T  cells  to 
cause the regression of its tumor. First, it was shown with two different immu- 
nogenic tumors (2,  3) that in order for passively transferred sensitized T  cells 
from  immunized donors  to  cause  the  complete  regression  of an  established 
tumor, the tumor-bearing recipient needs to have been made T  cell deficient by 
thymectomy and lethal irradiation, and then restored with bone marrow (TXB 
mice) ~  or immunodepressed by treatment with cyclophosphamide (4) or exposure 
to sublethal irradiation (5).  It was revealed next that tumor regression in TXB 
test recipients caused by the passive transfer of immune T  cells can be inhibited 
by the transfer of T  cells from immunocompetent tumor-bearing donors. It was 
hypothesized, on the basis of this and other evidence (6), that progressive growth 
of an immunogenic tumor eventually evokes the generation of a mechanism of 
T  cell-mediated immunosuppression. 
However, the demonstration that tumor-bearing mice acquire suppressor T 
cells  does not in  itself provide a  satisfactory explanation of how tumors with 
transplantation  rejection antigens escape  destruction  by  the  immune  system. 
What is needed in addition is evidence that suppressor T  cells either can prevent 
an antitumor immune response from developing or can down-regulate an im- 
mune response that already is in progress. In support of the latter possibility are 
numerous descriptions in the literature of the acquisition and subsequent loss by 
a host with a progressive tumor of a paradoxical state of concomitant immunity 
that enables the host to prevent the growth of an implant of cells of that tumor 
(reviewed in 7).  It seems reasonable to suggest, therefore, that the function of 
suppressor T  cells would be to down-regulate a concomitant antitumor immune 
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response before it develops sufficiently to destroy the tumor. 
This paper will show that early growth of the meth A fibrosarcoma evokes the 
generation in its syngeneic host of a  mechanism of concomitant immunity that 
can be passively transferred to y-irradiated recipients with Ly-l-2  + T  cells and 
is paradoxically expressed against an established tumor. It will show, in addition, 
that concomitant immunity and the Ly-l-2  + effector T  cells that mediate it are 
progressively lost after day 9  of tumor growth, and that this is associated with 
the progressive acquisition of Ly-l÷2  -  suppressor T  cells capable of suppressing 
the expression of passively transferred immunity against an established tumor in 
TXB recipients. 
Materials and Methods 
Mice.  Specific-pathogen-free BALB/c and CB6FI (BALB/c ×  C57BL/6) mice were 
supplied by the Trudeau Institute Animal Breeding Facility. They were known to be free 
of viral pathogens as evidenced by the results of routine screening performed by the 
Diagnostic Testing Service of Microbiological Associates,  Bethesda, MD. 
Tumors.  The  methylcholanthrene-induced  meth  A  fibrosarcoma,  syngeneic  in 
BALB]c mice,  was  originally obtained  from  Dr.  Lloyd Old  of the  Memorial  Sloan- 
Kettering Cancer Center, New York. To ensure that all of the experiments in a given 
study were performed with the same stock of tumor cells,  the tumor was grown as an 
ascites  in  the  peritoneal  cavities  of a  large  number  of BALB/c  mice,  harvested  in 
heparinized (5  IU/ml) phosphate-buffered saline (PBS),  pooled, washed in PBS, resus- 
pended in Fisher's medium (Gibco Laboratories, Grand Island, NY) containing 20% fetal 
calf serum (FCS) and 10% dimethyl sulfoxide, and cryopreserved in small volumes over 
liquid nitrogen. For each experiment a vial was thawed, the cells washed in PBS, and 2 × 
10  ~ of them used to initiate ascites tumors in CB6F1 mice. After 6 d of intraperitoneal 
growth, the tumor cells were harvested in heparinized PBS, washed in PBS, and resus- 
pended appropriately in  PBS for implanting in experimental animals.  Primary tumors 
were initiated in the midline of the belly region by intradermal injection of 106 meth 
A cells.  For challenge experiments, the same number of tumor cells were implanted in 
the right hind footpad. In the case of intradermal tumors, tumor growth was followed by 
measuring changes against time in the means of two perpendicular diameters. Footpad 
tumors were followed by measuring changes against time in the dorsoventral thickness of 
the foot with dial calipers. 
Immunization.  Mice were immunized against  the  meth A  fibrosarcoma by injecting 
them intradermally with an admixture of 106 meth A cells and 100 #g of formalin-killed 
Propionicbacterium acnes (C. parvum  from Burroughs Wellcome Co.,  Research Triangle 
Park, NC).  It has been shown (8) that this results in a 9-d period of progressive tumor 
growth and then complete tumor regression. Regression is associated with the acquisition 
of immunity to an implant and of T  cells capable of passively transferring immunity to 
normal recipients. 
T  Cell-deficient Mice.  Mice  were  made  T  cell  deficient (TXB)  at  6  wk  of age  by 
thymectomy followed 7 d  later by lethal (900 rad) 3" radiation from a  lSVCs source that 
delivered a midphantom dose rate of 30 rad/min. The mice were given 5 ×  10  n syngeneic 
bone marrow cells immediately after irradiation and were used in experiments after a 
further 4-6 wk. 
Passive Transfer of Immunity.  Immunized or tumor-bearing donor mice were killed by 
cervical dislocation and a  single-cell  suspension of spleen cells  was prepared by dicing 
their spleens into small pieces and pushing the pieces gently through a 60-mesh stainless 
screen into PBS. The resulting cell suspension was triturated with a pasteur pipette to 
break up clumps and passed through six layers of sterilized surgical gauze to remove 
debris.  The cells were  then washed  in  PBS and resuspended  in  PBS for intravenous 
infusion via a  lateral  tail vein into TXB or sublethally (500 rad) 3"-irradiated,  tumor- 
bearing recipients. 
Antibodies.  Hybridomas secreting monoclonal anti-Thy-l.2 (30-H12), anti-Ly-1  (53- NORTH AND BURSUKER  1297 
7.313), and anti-Ly-2 (53-6.72)  antibody (9) were obtained from the Salk Institute, La 
Jolla, CA. They were grown to 5 ×  106/ml in RPMI medium (Gibco  Laboratories) with 
10% FCS and antibiotics and the cultures were subjected to centrifugation in order to 
pellet the cells and debris. The supernatants were dispensed in small volumes, frozen, and 
stored at -20°C until required. Rabbit serum was used as a source of complement. It was 
obtained from rabbits bred at the Trudeau Institute and selected on the basis of minimal 
toxicity of their sera  for mouse thymocytes. Mouse anti-rat IgG serum was raised by 
injecting mice with 100 #g of rat IgG (Cappell Laboratories, Cochranville, PA) in Freund's 
complete adjuvant. The mice were given two additional injections of 100 #g of rat IgG in 
incomplete adjuvant and were bled 6 d later. Their sera were pooled and stored at -20°C 
until required. 
For deletion of T cells, donor spleen cells were incubated at 2 ×  107/ml in a 1:5 dilution 
of the anti-Thy-l.2 supernatant at 4°C for 30 min and then in a  1:10 dilution of rabbit 
serum at 37°C for 30  min. The cells were then washed and resuspended in PBS  for 
intravenous infusion. For depletion of Ly T  cell subsets,  spleen cells were incubated at 2 
×  107/ml in a  1:5 dilution of anti-Ly-1 or anti-Ly-2 supernatant at 4°C for 30 min. The 
cells were then washed in PBS and resuspended in a  1:50 dilution of mouse anti-rat IgG 
and incubated at 4°C for a further 30 min. They were then washed and incubated in 
rabbit complement as above and washed and resuspended for intravenous infusion. All 
reagents were diluted in RPMI medium containing 1% FCS. 
Results 
Acquisition and Loss of Immunity to a Challenge Implant.  Concomitant immunity 
is defined as the acquired ability by a  host with a  progressive tumor to inhibit 
the growth of a  challenge implant of cells of the same tumor given at another 
site. The fact that progressive growth of the Meth A  fibrosarcoma results in the 
generation and  subsequent  loss of concomitant immunity is  evident from  the 
results of an  experiment  that measured growth of a  challenge implant of 106 
tumor cells injected in the right hind footpad of mice bearing 3,  6,  9,  16, and 
20 d  intradermal tumors.  It can be seen in Fig.  1 that immunity to the growth 
of the challenge implant was acquired by day 6 of growth of the primary tumor, 
was present on day 9, and had almost completely decayed by day 16. 
Concomitant hnmunity Is Associated with Acquisition  of Ly-l-2 + T  Cells Capable of 
Adoptively  Immunizing  Against  an  Established  Tumor.  Although  the  preceding 
results leave no doubt that concomitant immunity is acquired and subsequently 
lost by mice bearing the Meth A  fibrosarcoma, the identification and character- 
ization  of the  cells  that  mediate  this  immunity required  that  it  be  passively 
transferred to appropriate  recipients,  preferably against an established tumor. 
However,  past  attempts  in  this  laboratory  to  passively  transfer  concomitant 
immunity systemically, even against the growth of tumor implant, have failed. It 
was for this reason that the Winn neutralization assay (10) was used to show that 
concomitant immunity is T  cell mediated (11).  Recent publications (5,  6) from 
this laboratory have revealed the reason for past failures to demonstrate adoptive 
immunization against established tumors: To passively transfer immunity against 
an established tumor with T  cells from preimmunized donors, it is necessary to 
use immunodepressed recipients that are incapable of generating suppressor T 
cells that prevent passively transferred immunity from being expressed.  It was 
reasoned, therefore, that it would be possible to adoptively immunize against an 
established  tumor  with  lymphoid  cells  from  a  concomitantly  immune  tumor 1298  CONCOMITANT  ANTITUMOR  IMMUNITY  AND  IMMUNOSUPPRESSION 
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FIGURE  1.  The generation and subsequent decay of concomitant immunity to growth of a 
tumor implant in mice bearing a  progressive meth  A  tumor. (Top) Growth of the primary 
meth A  tumor growing from an intradermal implant in the belly region. (Bottom) Growth of 
an intra-footpad implant of 106 meth A cells given to control mice and to tumor-bearing mice 
on day 3, 6, 9,  16, or 20 of tumor growth (numbers on individual graphs). Means of five mice 
per group. 
bearer, provided that the recipient is immunodepressed and has a smaller tumor 
than the donor. 
Results supporting  this  reasoning  are  shown  in  Fig.  2,  in  which  the  passive 
transfer of one organ equivalent (1.5 ×  108) of spleen cells from donors with a 
9-d intradermal  tumor caused, after a  2-3-d delay, complete regression of a  3-d 
tumor in recipients, provided the recipients were given 500 rad of 3' radiation  1 
h  before they received spleen cells•  At the time of passive transfer,  the donor 
tumor had  an  ~8-ram  diam,  whereas the diameter  of recipient  tumor was ~2 
mm.  Fig.  2  shows,  in  addition,  that  the  spleen  cells that  passively transferred 
immunity to irradiated  recipients were T  cells, as evidenced by their functional 
elimination by treatment with anti-Thy-l.2 antibody and complement. NORTH AND BURSUKER  1299 
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FIGURE 2.  Evidence that  concomitant immunity can  be passively transferred  with T  cells 
and  paradoxically expressed against  an established  tumor  in recipients given 500  rad of ~, 
radiation 1 h before passive transfer. An intravenous infusion (arrow) of 1.5 X 108 spleen cells 
from  donors  bearing  a  9-d  tumor  was  given to  nonirradiated  (IMMUNE)  and  irradiated 
(500 R +  IMM) recipients with a  3-d tumor. Spleen cells caused regression of the recipient's 
tumor only if the recipient was irradiated. The spleen cells that transferred immunity were T 
cells, as evidenced by their susceptibility to treatment with anti-Thy°1.2 antibody and comple- 
ment. 
The Ly phenotype of the T  cells that transfer concomitant immunity also was 
investigated. The results in Fig.  3 show that they were Ly-l-2  + T  cells, in that 
their capacity to passively transfer immunity against an established tumor was 
completely ablated by treatment with anti-Ly-2 antibody and complement, but 
was not affected at all by treatment with anti-Ly-1 antibody and complement. In 
fact, treatment with the anti-Ly-1 reagent, more often than not, enhanced the 
level of concomitant immunity transferred. 
Kinetics of Generation and Loss of T Cells that Transfer Concomitant Immunity.  The 
foregoing results  show  that  growth  of the  meth  A  fibrosarcoma evokes  the 
generation in  its  host of a  state of concomitant immunity to  the growth of a 
tumor implant. They also show that the concomitant immunity can be passively 
transferred with Ly-l-2  + T  cells and expressed against an established tumor in 
~-irradiated recipients.  They show again  that concomitant immunity, as mea- 
sured by resistance to the growth of a tumor implant, is lost after day 9 of growth 
of the primary tumor. We predicted, therefore, that T  cells capable of passively 
transferring immunity also would be lost after day 9. We measured changes in 
the capacity of one organ  equivalent (~1.5  ×  108) of spleen  cells from mice 
bearing a 3, 6, 9,  12,  15, or 18 d tumor to cause the regression of a standard 3- 
D tumor growing in recipients given 500 rad of'y radiation 1 h before receiving 
spleen  cells.  Passive  transfer  was  performed at  a  single  time  with  recipients 
bearing a standard-sized tumor. 1300  CONCOMITANT  ANTITUMOR  IMMUNITY  AND  IMMUNOSUPPRESSION 
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FIGURE 3.  The T  cells that passively transferred concomitant immunity and caused regres- 
sion of an established tumor in 3,-irradiated recipients were functionally eliminated by treat- 
ment with anti-Ly-2 antibody and complement, but not by anti-Ly-1 antibody and complement. 
In this experiment, all recipients were given 500 rad of ~, radiation 1 h before receiving spleen 
cells on day 3 (arrows). Means of five mice per group. 
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FIGURE 4.  Kinetics of generation, during progressive tumor growth, of T  cells capable of 
passively transferring immunity against an established tumor in irradiated recipients. Recipients 
bearing a 3-d tumor were given 500 rad of ~t radiation and infused 1 h later (arrow) with one 
organ equivalent (-1.5  X  l0  s) of spleen cells from donor mice with a  3 (A), 6 (I), 9 (b),  19 
(O), 15 (+), or 18 (0) d tumor. T  cells capable of passively transferring immunity were already 
generated by day 6, reached peak numbers on day 9 (complete regression), and were rapidly 
lost after day 9. Means of five mice per group. NORTH AND BURSUKER  1301 
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FIGURE 5.  Results in  Fig.  4  expressed as changes in  the index of concomitant immunity 
(bottom) which was calculated as the difference between the growth of the tumor in control 
recipients and its growth in recipients of donor T  cells on day  16 of the experiment. (Top) 
Growth of the donor tumor. 
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FIGURE 6.  Evidence that the extent to which the 7-irradiated recipient's tumor underwent 
regression was dependent on the number of donor spleen cells infused intravenously. The 
recipients were given 500 tad of ~, radiation and were infused 1 h  later on day 3 of tumor 
growth (arrow) with  1 (1.8  x  108),  0.5  (9 X  107), or 0.25 (4.5  x  107) organ equivalents of 
spleen cells from donor mice with a 9-d tumor. Means of five mice per group. 
The results in Fig. 4 show that splenic T  cells capable of adoptively immunizing 
against  an  established  tumor  were  acquired  between  days  3  and  6  of tumor 
growth, reached peak numbers on day 9, and were rapidly lost over the next 3 
d.  It was only on day 9  that  the  spleen contained  enough  sensitized T  cells to 
cause complete regression of the recipient tumor.  Fig. 5 shows the same results 1302  CONCOMITANT  ANTITUMOR  IMMUNITY  AND  IMMUNOSUPPRESSION 
expressed as the difference between the growth of tumors in control recipients 
and their growth in recipients of immune cells on day 16. This enabled concom- 
itant  immunity to  be plotted as an  index of immunity against time of tumor 
growth, and serves to show more clearly the kinetics of acquisition and loss of 
immunity. 
It  is  assumed  in  interpreting  these  differences, however,  that  the  level  of 
passively transferred concomitant immunity expressed by the recipients is pro- 
portional to the number of tumor-sensitized T  cells infused. The results of an 
experiment  that  measured  the  immunity  transferred  against  an  established 
recipient tumor with graded numbers of spleen cells from donors with a  9-d 
tumor are shown in Fig. 6.  They reveal that both the speed and the degree to 
which the recipients' tumor underwent regression depended on the number of 
donor cells infused, but that even as few as 0.25 organ equivalents (5 x  107) of 
donor spleen cells caused appreciable tumor regression to occur. Therefore, the 
small degree of tumor regression caused by the passive transfer of day 15 T cells, 
as  shown  in  Fig.  4,  indicates  that  by  this  stage  of tumor  growth  the  donor 
possessed <25%  of the sensitized T  cells that it possessed at peak response on 
day 9. 
Kinetics of the Generation of Suppressor T Cells.  Previous publications from tbis 
laboratory (2, 3) show that progressive growth ofimmunogenic tumors eventually 
results in the generation of splenic suppressor T  cells that are capable, on passive 
transfer, of preventing the regression of established tumors in TXB recipients 
infused with T  cells from preimmunized donors.  Another of our publications 
(12) revealed that the suppression of adoptive immunity depends on the ability 
of infused suppressor T  cells to inhibit the generation of cytolytic effector T 
cells in the adoptively immunized TXB recipients. However, all previous studies 
in this  laboratory of tumor-induced immunosuppression by suppressor T  cells 
used suppressor  T  cells that  were harvested from donor mice bearing a  14-d 
tumor. We needed to determine whether suppressor T  cells are acquired before 
day 14,  to explain the rapid loss of effector T  cells after day 9.  This involved 
measuring the ability of one organ equivalent (1.5  x  108) of spleen cells from 
mice with a  3, 6,  9,  12,  15,  or  18 d  tumor to inhibit the capacity of 1.5  x  l0 s 
spleen cells from preimmunized donors to cause the regression of a  4-d tumor 
in  TXB  recipients.  Suppressor  T  cells were infused 3  h  after immune spleen 
cells. This assay is different, therefore, from the adoptive concomitant immunity 
assay, both in terms of the donors of immune T  cells and the type of recipients. 
It can  be  seen  in  Fig.  7  that  the capacity of immune spleen cells to  cause 
regression of an established tumor in TXB recipients was inhibited by passive 
transfer of spleen cells from tumor-bearing donors, provided that spleen cells 
were harvested from the donors on day 9 of tumor growth or later. There was 
a progressive increase in the number of suppressor T  cells between days 9 and 
15. By subtracting the size of tumors in recipients of immune cells from the sizes 
in recipients of immune cells plus suppressor T cells on day 21 of the experiment, 
a suppressor index was obtained that we plotted against the growth of tumors in 
donors of suppressors (Fig.  8).  Suppressor T  cells were present in appreciable 
numbers on day 9 of tumor growth (Fig. 8) at the same time that effector T  cells NORTH AND BURSUKER  1303 
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FIGURE 7.  Changes against time in capacity of one organ equivalent (1.5  X  l0  s) of spleen 
cells from donor  mice bearing a  progressive tumor  to suppress  the expression of adoptive 
immunity in TXB tumor-bearing recipients. The test tumor  in TXB recipients underwent 
complete regression after infusion (arrow) of 1.5 x  10 s spleen cells from preimmunized donors 
(IMM). Shown are changes in the ability of one organ equivalent (1.5  ×  10  s) of spleen cells 
from mice with a  6, 9,  12,  15, or 18 d  tumor (numbers on individual graphs) to inhibit the 
antitumor function of the passively transferred immune spleen cells. The spleen cells of tumor- 
bearing donors were infused 3 h after immune spleen cells.  Means of five mice per group. 
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FIGURE 8.  The  results  in  Fig.  7  expressed  as a  suppressor  index  that  was  obtained  by 
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of immune plus suppressor  cells on day 21  of the experiment (bottom). (Top)  Growth of the 
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FIGURE 9.  The cells from donors with a  15-d tumor that were capable, on passive transfer, 
of inhibiting the regression of an established tumor in TXB recipients were Ly-1 +2- T  cells. 
Their suppressor function was not eliminated by treatment with anti-Ly-2 plus complement, 
but was totally eliminated by treatment with anti-Ly-I antibody and complement.  Immune 
and suppressor T  cells were infused 3 h apart on day 4 of tumor growth. Means of five mice 
per group. 
were present in peak numbers, as shown in a  preceding section. This paradox 
will be explained later. 
Suppressor  Cells Are Ly-l÷2  -  T  Cells.  The standard suppressor assay was used 
to determine the Ly phenotype of suppressor T  cells in 15-d tumor bearers. The 
results  in  Fig.  9  show  unequivocally  that,  unlike  effector  T  cells  capable  of 
passively transferring concomitant immunity, the T  cells that transferred  sup- 
pression were Ly-l+2 -  cells, as evidenced by their elimination by treatment with 
anti-Ly-1 antibody and complement, but not with anti-Ly-2 antibody and com- 
plement. 
Discussion 
A central problem in tumor immunology has been to explain why tumors with 
transplantation rejection antigens, capable of specifically immunizing their im- 
munocompetent hosts against growth of a tumor implant, are not destroyed by 
an antitumor immune response.  Similar to previous findings with the meth A 
fibrosarcoma (2) and PS15 mastocytoma (3),  this paper shows that progressive 
growth of an immunogenic tumor eventually evokes the generation of suppressor 
T  cells whose function can be measured by their ability to suppress, on passive 
transfer,  the expression of adoptive immunity against an established tumor in 
TXB recipients infused with T  cells from preimmunized donors.  It shows,  in 
addition, that the suppressor T  cells were of the Ly-1 ÷2- phenotype, in that they 
were functionally eliminated by treatment with anti-Ly-1 antibody and comple- 
ment, but not by an anti-Ly-2 antibody capable of completely eliminating effector 
T  cells (see below). Suppressor T  cells were first generated on about day 9  of NORTH AND BURSUKER  1305 
tumor  growth  when  the  tumor  was  7-8  mm  in  diameter,  and  increased  in 
number as the tumor increased in size.  These findings appear more significant 
in light of the additional information that the onset of production of Ly-l÷2  - 
suppressor  T  cells  was  associated  with  the  onset  of progressive  decay  of a 
preceding concomitant antitumor immune response that was measured in terms 
of both the acquisition of immunity to growth of an implant of tumor cells and 
the acquisition of T  cells capable of adoptively immunizing against an established 
tumor in irradiated recipients. The concomitant immune response was generated 
after  day  6  of tumor  growth,  peaked  on  day  9,  and  then  rapidly  decayed. 
Moreover, the T  cells that transferred concomitant immunity were Ly-l-2  +, in 
that  they  were  totally  eliminated  by  treatment  with  anti-Ly-2  antibody  and 
complement but not with the same anti-Ly-1 reagent that eliminated suppressor 
T  cells. 
This apparently clear-cut absence of Ly-1  antigen on effector T  cells might 
seem surprising,  in  view of the demonstration by others (13)  that all  T  cells 
display  Ly-1  antigen to  some degree. However, it  remains to  be  determined 
whether the expression of Ly-1 antigen on all T  cells depends on the strain of 
mouse used and on whether the T  cells are harvested from normal mice or from 
mice generating an active immune response. In any case, it is apparent that not 
enough Ly-1 antigen was present on the effector T  cells generated in response 
to  the meth A  to  make them  susceptible to  complement-mediated lysis  after 
treatment with a particular anti-Ly-1 reagent. 
The immune response to the progressive growth of the meth A fibrosarcoma 
is represented diagrammatically in Fig. 10. It is meant to show that a tumor of a 
certain  minimal  critical  size  is  required  to  evoke the  generation  of Ly-l-2  + 
effector T  cells and that a tumor of a larger critical size is required to evoke the 
generation of Ly-l+2  - suppressor T  cells that down-regulated the production of 
effector T  cells.  It also shows that immunosuppression is not a  sudden, all-or- 
nothing  event  but  involves  a  progressive  increase  over  time  in  the  ratio  of 
suppressor T  cells to effector T  cells, meaning that effector and suppressor T 
cells  can  coexist.  This  is  probably  the  reason  why treatment  with  anti-Ly-2 
antibody and complement always resulted  in  a  slight  increase in  the level  of 
suppression passively transferred and why treatment of day 9-10  spleen cells 
with anti-Ly-1 antibody and complement resulted in an increase in the level of 
concomitant immunity transferred. Taken as a whole, the results in Fig.  10 are 
consistent with the hypothesis that immunogenic tumors are not rejected by their 
immunocompetent hosts,  because  the  immune response  they evoke is  down- 
regulated by suppressor T  cells before an adequate number of effector T  cells is 
generated to destroy the tumor. In the case of the meth A fibrosarcoma, there 
is  only  ~3-4  d  from when  the  tumor  becomes large  enough to  trigger  the 
generation of effector T  cells to  when it  is  large enough to  provide  enough 
antigen to trigger the generation of suppressor T  cells. This narrow window for 
generating effector T  cells is the result of the syngeneic tumor being a  weak 
replicating  antigen.  It  is  likely that  other replicating antigens,  such as  those 
represented by bacteria and protozoa that cause chronic infections, can give rise 
to the same sequence of immunological events as the meth A. Experiments with 
BALB/c mice infected with Leishmania  tropica (14) show that progressive growth 1306  CONCOMITANT  ANTITUMOR  IMMUNITY  AND  IMMUNOSUPPRESSION 
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FIGURE I0.  Diagrammatic representation  of the immune response to a  progressive immu- 
nogenic tumor of the type represented by the meth A fibrosarcoma. After the tumor reaches 
a critical minimum size it provides enough antigen to evoke the generation of Ly-l-2  + effector 
T  cells.  However, a  short period of additional tumor growth provides antigenic conditions 
that favor the generation of Ly-l+2  -  suppressor  T  cells that  function to down-regulate the 
production of Ly-t-2* effector T  cells. Consequently, not enough effector T  cells are made 
to destroy the tumor. 
of this parasite engenders the production of Ly-l+2- suppressor T  cells that are 
capable, on passive transfer, of suppressing the expression of immunity against a 
Leishmania challenge inoculum in immunized recipients. For several reasons, the 
suppression ofanti-Leishmania immunity is similar to the suppression ofantitumor 
immunity described here.  First,  both  models are based  on  the response  to  a 
replicating antigen  that  needs  to  expand  to  a  certain  critical quantity before 
suppressor T  cells are generated. Second, the assay for suppressor T  cells, in 
both cases, is an in vivo one that relies on the ability of suppressor T  cells to 
function after they are passively transferred. Third, because in both cases the T 
cells that passively transfer suppression are of the Ly-1 +2- phenotype, they are 
different from the T  cells that have been shown to suppress antibody responses 
(15, 16), delayed-type hypersensitivity, and contact sensitivity (17). This does not 
make them unique, however, because there are other descriptions of Ly-l+2  - 
suppressor T  ceils in the literature. For example, the in vivo suppression of acute 
graft-vs.-host disease is mediated by Ly-1 +2- T  cells (18, 19) as is the suppression 
in vitro of the cytolytic T  cell responses to major (20) and minor (21) histocom- 
patibility  antigens.  In  addition,  it  has  been  shown  more  recently  (22)  that 
ultraviolet light-facilitated induction of the suppression of sensitivity to dinitro- 
fluorobenzene is associated with the generation of Ly-1 ÷2- cells that can transfer 
afferent suppression to irradiated recipients. Again, Ly-l+2  -  T  cells have been 
shown to  exclusively suppress  the H-2-restricted interaction of helper T  cells 
with B cells (23). 
This is not to say that the passively transferred Ly-l+2  -  suppressor cells that 
suppress  immunity to the meth A  fibrosarcoma are the ultimate mediators of 
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suppressors that give rise to functional  Ly-l-2  ÷ suppressor T  cells, as has been 
postulated to occur in other models of suppression (17, 24). Even so, the failure 
of treatment  with anti-Ly-2 antibody and complement to have any effect at all 
on the  T  cells that  passively transfer  suppression  certainly does not support a 
role  for  Ly-l-2  + suppressor  T  cells, particularly  when  one considers  that  the 
suppressor T  cells were harvested from tumor-bearing donors in which suppres- 
sion was being actively expressed. 
Ly-l+2  -  T  cell suppressors of concomitant immunity to the meth A  fibrosar- 
coma appear  to have  little resemblance  to the  Ly-l-2  + T  cells that have been 
shown to suppress immunity to the S1509a sarcoma syngeneic in A/J mice. This 
well-studied model of tumor-induced suppression (25, 26) is based on the dem- 
onstration that T  cells from mice with an established S 1509a tumor are capable, 
on passive transfer,  of inhibiting  to a  certain  extent the capacity of immunized 
mice to prevent the growth of an implant of tumor cells. The finding that these 
Ly-l-2  + suppressor T  cells are generated as early as 24 h  after implanting  106 
S1509a  cells  subcutaneously  (26)  makes  them  quite  different  from  meth  A- 
induced suppressor T  cells, which are not generated until 9 d of tumor growth. 
Presumably,  suppression  of anti-S1509a  immunity  is  an  example  of T  cell- 
mediated  unresponsiveness  (passive  suppression),  in  contrast  to  active  T  cell- 
mediated suppression of an already ongoing mechanism of concomitant immu- 
nity, as seen with the meth A fibrosarcoma (2) and P815 mastocytoma (3). 
The specificity of active suppression of anti-meth  A  immunity was not inves- 
tigated  in  this  study.  However,  the  same  type  of  suppression  was  recently 
investigated (27) in this laboratory with two DBA/2 tumors, the P815 mastocy- 
toma and  P388 lymphoma.  It was shown by reciprocal passive transfer  experi- 
ments that the T  cells that transfer immunity and the T  cells that suppress it are 
specific for the tumor that evokes their generation.  This is in keeping with the 
knowledge that meth A-induced immunosuppression does not cause the host to 
display a  state of generalized immunosuppression,  as evidenced by retention of 
normal capacities to reject a tumor allograft (2) and to generate T  cell-mediated 
immunity to infection with viral and bacterial pathogens (28). 
Regarding  the  type  of antitumor  immunity  generated  against  the  meth  A 
fibrosarcoma, it has been demonstrated  repeatedly over a  number of years (7) 
that progressive tumor growth can evoke the generation of a paradoxical, short- 
lived state of concomitant immunity, as measured by the acquisition and subse- 
quent  loss  of  immunity  to  the  growth  of a  challenge  implant.  Even  more 
paradoxical  is  the  demonstration  here  that  this  immunity  can  be  passively 
transferred and expressed against an established tumor in "r-irradiated recipients. 
However, the  paradox  becomes more apparent  than  real  when  one considers 
that the donor's 9-d tumor was twice the size of the recipient's 3-d tumor at the 
time  of transfer.  It  is  not  unreasonable  to  suggest,  therefore,  that  the  donor 
would have been able to reject its own tumor if its tumor on day 9 had been as 
small as the recipient's 4-d tumor. 
One might  also question  the  finding  that  the  effector T  cells that  passively 
transfer concomitant immunity to the meth A fibrosarcoma display the Ly-l-2  + 
phenotype of cytolytic T  cells on the grounds that recent publications (29) show 
that  Ly-l+2  -  T  cells  passively  transfer  immunity  to  tumor  allografts  at  the 1308  CONCOMITANT  ANTITUMOR  IMMUNITY  AND  IMMUNOSUPPRESS1ON 
exclusion of Ly-l-2  + T  cells.  This has been interpreted to mean that allografts 
are not rejected by cytolytic T cells but by a delayed-type hypersensitivity reaction 
mediated by  Ly-l+2  -  T  cells  in  the graft.  As  was pointed  out  recently (30), 
however,  the  interpretation  that  Ly-l+2  -  T  cells are  the  mediators  of graft 
rejection does not take into account the knowledge that the TXB mice which 
were routinely used as recipients in the experiments are able to contribute their 
own Ly-2  + cytolytic T  cells to the rejection process (30). Neither does it consider 
that  the  immunized donors  of allosensitized  T  cells  might possess  a  state  of 
immunological memory rather than active immunity. It was shown recently (12) 
that the passive transfer of tumor-sensitized memory T  cells does not cause the 
regression of a target tumor in TXB recipient mice until the recipients generate 
a cytolytic T  cell response of their own. The need for the generation of cytolytic 
T  cells would explain the delay of 1-2 wk after the passive transfer of sensitized 
T  cells before the expression of adoptive antitumor and antiallograft immunity. 
Presumably, the failure to show that Ly-2  + T  cells are able, on passive transfer, 
to reject a target graft is the result of the use of memory donors that have lost 
the sensitized Ly-2  + cytolytic T  cells generated as part  of the active immune 
response.  Studies  show that  Ly-2  ÷ T  cells can passively transfer immunity to 
allografts (31) and tumor syngrafts (32).  It even has been demonstrated that in 
vitro generated, interleukin 2-expanded cytolytic T  cells can passively transfer 
immunity locally (33) and systemically (34) against a tumor syngraft. 
The question of cytolytic T  cells versus memory T  cells as effectors of cell- 
mediated immunity leads to a comparison of the assays used in the present study 
to measure immunity and suppression. This is necessary to explain the contra- 
diction of finding peak numbers of immune T  cells on day 9 of tumor growth, 
according to one assay, but at the same time, appreciable numbers of suppressor 
T  cells according to the other. This can be explained by taking into account the 
fact that the assay for suppression is based on the ability of suppressor T  cells 
from tumor-bearing donors  to  inhibit,  on  passive  transfer,  the expression of 
passively transferred memory immunity against an established tumor in  TXB 
recipients. Because passively transferred immunity is not expressed in this assay 
for 6-8 d, any functionally immature suppressor T cells infused 3 h after immune 
T  cells would have plenty of time to mature into functional suppressor T  cells. 
It seems reasonable to suggest, therefore, that suppressor T  cells detected by the 
assay in donor spleens at the height of concomitant immunity on day 9 probably 
were not functionally mature at  that  time.  Nevertheless, they would need to 
mature very soon after day 9 to explain the rapid progressive decay of concom- 
itant immunity and loss of immune T  cells after this time. 
The assay for concomitant immunity was different in that the recipients were 
given 500  rad of 3' radiation  1 h  before passive transfer. This is an important 
difference,  because  recent  results  (to  be  published)  show  that  this  dose  of 
irradiation given on days 3-4 of tumor growth did not suppress the concomitant 
immune response of the recipient. Consequently the regression of an established 
tumor in y-irradiated recipients of Ly-l-2  + T  cells from tumor-bearing donors 
is mediated not only by donor T  cells but also by the recipient's own T  cells. 
The dose of irradiation does, however, greatly delay the generation of suppressor NORTH AND BURSUKER  1309 
T  cells.  These findings need to be considered in interpreting the results of any 
adoptive immunization experiment with irradiated recipients. 
Summary 
It was shown that the progressive growth of the immunogenic meth A fibro- 
sarcoma  in  its  semisyngeneic host  results  in  the  generation  of concomitant 
immunity to  the  growth  of a  tumor  implant.  The  generation  of immunity 
occurred between days 6  and 9  of tumor growth and was associated with the 
generation of sensitized T  cells that were capable, on passive transfer, of causing 
regression of  a 3-d tumor in 3,-irradiated recipients. After day 9 of tumor growth, 
concomitant immunity and the T  cells able to passively transfer it were progres- 
sively lost, and this was associated with the generation of splenic suppressor T 
cells able to suppress the expression of adoptive immunity against an established 
tumor in T  cell-deficient (TXB) recipients. The T  cells that passively transferred 
concomitant immunity were shown to be of the Ly-l-2  ÷ phenotype, in contrast 
to the T  cells that transferred suppression,  which were shown with the same 
reagents to be Ly-l÷2  -. The results are consistent with the hypothesis that the 
progressive growth of an immunogenic tumor results in the generation of Ly- 
1-2+-sensitized effector T  cells that fail to reach a number sufficient to destroy 
the tumor because their generation is down-regulated by tumor-induced Ly-1  ÷2- 
suppressor T  cells. 
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